Common Contracts

Licensing, development, manufacturing and marketing agreement for Amigal (migalastat HCl) for Fabry disease

Licensing, Development, Manufacturing and Marketing Agreement • January 30th, 2022 • Delaware

• Contract Type
  Licensing, Development, Manufacturing and Marketing Agreement
• Filed
  January 30th, 2022
• Jurisdiction
  Delaware

chaperone-ERT-coadministration, plus potentially up to $35 million within seven years following the launch of a coformulated chaperone-ERT product.